Early Transcatheter Mitral Valve Repair After Myocardial Infarction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorFundación para la Investigación Biosanitaria del Principado de Asturias

About this trial

To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined incidence of death and heart-failure associated hospitalisations at one-year follow-up, and quality of life and LV remodelling at two-year follow-up.

Eligibility criteria

Qualifiers

Patients with symptomatic moderate to severe or severe MR after acute MI

Age > 18 years

Disqualifiers

Primary MR (e.g. papillary muscle rupture)

EF ≤ 25%

Accepted for CABG

Presence of cardiogenic shock (AMR type 1)

Trial design

Treatments tested in this trial

  • Early transcatheter edge-to-edge mitral valve repair (TEER).
  • MitraClip
  • Optimal medical treatment

Treatment groups

250 Participants
are divided into 2 treatment groups

Sponsors and collaborators